Wegovy

• Could GLP-1 drugs help your mental health? New study finds a link

  Semaglutide, the active ingredient in GLP-1 drugs, was associated with a lower risk of worsening mental health, a study published in Lancet Psychiatry found.

  Health

  5 hours
  
• Many regain weight after stopping GLP-1 drugs, data shows. Here’s why

  People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.

  Health

  Jan 8
  
• Advertisement
• Wegovy weight loss pill is now available for sale in U.S.

  The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ground lost to U.S. rival Eli Lilly.

  Health

  Jan 6
• Advertisement
• The Wegovy weight loss pill could come to Canada. What we know

  The FDA approved the one-a-day Wegovy pill, the first oral GLP-1 medication for obesity in the U.S., Wegovy manufacturer Novo Nordisk said in a statement Tuesday.

  Health

  Dec 24, 2025
• U.S. FDA approves Wegovy weight-loss pill in industry first

  The approval gives Novo Nordisk a leg up in the race to market a potent oral medication for shedding pounds as it looks to regain lost ground from rival Eli Lilly.

  Health

  Dec 22, 2025
• Wegovy won’t be in Canadian public drug plans as Novo Nordisk refuses talks

  Negotiations that could have led to coverage for weight-loss drug Wegovy under Canadian public health plans are not moving forward.

  Health

  Dec 3, 2025
• Ozempic, Wegovy makers Novo Nordisk announce 9K layoffs in restructuring

  Ozempic and Wegovy maker Novo Nordisk says it will layoff about 9,000 employees of its global workforce as it restructures in an attempt to fend off competition.

  World

  Sep 10, 2025
• University of Manitoba studies Ozempic marketing

  Researchers at the University of Manitoba are looking at how marketing for drugs like Ozempic and Wegovy influence peoples' views on food, hunger, and weight.

  Health

  Jul 23, 2025
• Advertisement
• Ozempic, Wegovy linked to rare cases of eye disorder, EMA says

  Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide.

  Consumer

  Jun 6, 2025
• Advertisement
• Weight-loss drug Wegovy use is up 50% among U.S. teens, study shows

  A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

  Health

  Jun 3, 2025